PE20191837A1 - Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas - Google Patents

Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas

Info

Publication number
PE20191837A1
PE20191837A1 PE2019002069A PE2019002069A PE20191837A1 PE 20191837 A1 PE20191837 A1 PE 20191837A1 PE 2019002069 A PE2019002069 A PE 2019002069A PE 2019002069 A PE2019002069 A PE 2019002069A PE 20191837 A1 PE20191837 A1 PE 20191837A1
Authority
PE
Peru
Prior art keywords
alkyl
hydrogen
tracks
leave
system including
Prior art date
Application number
PE2019002069A
Other languages
English (en)
Inventor
Christopher M Adams
Myriam April
Tanzina Fazal
Cornelia Jutta Forster
Edward Charles Hall
Cameron Chuck-Munn Lee
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62116508&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20191837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20191837A1 publication Critical patent/PE20191837A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Referido a un sistema de administracion de farmacos que comprende D-R, que esta representado por la Formula (I), donde D es un resto biologicamente activo que comprende al menos una amina primaria o secundaria o un atomo de nitrogeno anular de un anillo de azaheteroarilo; y R es un ligante adecuado para la liberacion del resto biologicamente activo D; R1 es hidrogeno o C1-C4 alquilo; R1a es hidrogeno o C1-C4 alquilo, entre otros; R2 se selecciona independientemente entre C1-C4 alquilo o oxo, entre otros; a es 0, 1, 2, 3 o 4; R3 es hidrogeno o C1-C4 alquilo; R3a es hidrogeno, C1-C4 alquilo, entre otros; Y es C(O)R4, C(O)OR4, entre otros; y Z es CH-L-A, CH-A, N-L-A o N-A, donde L es un enlazador bivalente opcionalmente sustituido; A es hidrogeno, C1-C8 alquilo, entre otros. Tambien se refiere a un portador que se conjuga al farmaco a traves del ligante estable. Dicho sistema de administracion es util para el tratamiento de trastornos musculoesqueleticos.
PE2019002069A 2017-04-20 2018-04-19 Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas PE20191837A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487888P 2017-04-20 2017-04-20
PCT/IB2018/052740 WO2018193408A1 (en) 2017-04-20 2018-04-19 Sustained release delivery systems comprising traceless linkers

Publications (1)

Publication Number Publication Date
PE20191837A1 true PE20191837A1 (es) 2019-12-30

Family

ID=62116508

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019002069A PE20191837A1 (es) 2017-04-20 2018-04-19 Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas
PE2021000630A PE20211281A1 (es) 2017-04-20 2018-04-19 Sistemas de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021000630A PE20211281A1 (es) 2017-04-20 2018-04-19 Sistemas de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas

Country Status (26)

Country Link
US (3) US10751417B2 (es)
EP (1) EP3612233A1 (es)
JP (1) JP7323453B2 (es)
KR (1) KR20190137888A (es)
CN (1) CN110603060A (es)
AR (1) AR111481A1 (es)
AU (1) AU2018255933B2 (es)
BR (1) BR112019021810A2 (es)
CA (1) CA3057590A1 (es)
CL (1) CL2019002969A1 (es)
CO (1) CO2019011577A2 (es)
CR (1) CR20190479A (es)
CU (1) CU20190082A7 (es)
DO (1) DOP2019000268A (es)
EA (2) EA201992484A1 (es)
EC (1) ECSP19075134A (es)
IL (1) IL269991B2 (es)
JO (1) JOP20190245A1 (es)
MA (1) MA50260A (es)
MX (1) MX2019012447A (es)
PE (2) PE20191837A1 (es)
PH (1) PH12019502325A1 (es)
SG (1) SG11201908740VA (es)
TW (1) TW201842935A (es)
UY (1) UY37686A (es)
WO (1) WO2018193408A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016301282B2 (en) 2015-08-03 2022-03-17 Children's Medical Center Corporation Charged ion channel blockers and methods for use
ES2755815T3 (es) 2016-09-13 2020-04-23 Allergan Inc Composiciones de toxina de Clostridium no proteicas estabilizadas
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
AR116566A1 (es) * 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
EP3937945A4 (en) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. CHARGED ION CHANNEL BLOCKERS AND METHODS OF USE
MA55320A (fr) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueurs de canaux ioniques substitués par un ester et méthodes d'utilisation
JP2022527690A (ja) 2019-03-11 2022-06-03 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
WO2020254607A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254611A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254617A1 (en) * 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
US11795320B2 (en) * 2019-09-20 2023-10-24 Bausch + Lomb Ireland Limited Grafted polymer and use thereof
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN111110829A (zh) * 2019-12-24 2020-05-08 浙江大学 一种纳米防御素凝胶支架及其制备方法和应用
JP2023517604A (ja) 2020-03-11 2023-04-26 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
CN111285736A (zh) * 2020-04-09 2020-06-16 郑州先利达化工有限公司 含亚磷酸钾、矿源黄腐酸钾、聚谷氨酸的药肥组合物
CN114129780B (zh) * 2020-09-03 2022-06-28 天津大学 一种光控释放一氧化氮的复合水凝胶的制备及应用
WO2023034299A1 (en) * 2021-08-31 2023-03-09 The Research Foundation For The State University Of New York Shear-thinning hydrogels and uses thereof
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CN115074402B (zh) * 2022-07-20 2022-11-18 点滴(南京)生物科技有限公司 一种采用酶法合成的γ-聚谷氨酸钠交联水凝胶及其合成方法
WO2024073588A1 (en) * 2022-09-28 2024-04-04 Board Of Regents, The University Of Texas System Respiratory dry powder delivery
CN115947956B (zh) * 2022-10-09 2024-03-19 西北农林科技大学 一种基于细菌纤维素纳米晶的皮克林纳米乳液及应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3737523A1 (de) 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0712635B1 (en) 1994-05-13 2003-05-02 Kuraray Co., Ltd. Medical polymer gel
WO1998009987A1 (en) 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
EP1374908A3 (en) 1998-10-09 2004-03-24 The Regents Of The University Of Michigan Polymer-drug conjugates comprising hydrazide linkers
JP2004524297A (ja) 2001-01-23 2004-08-12 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニスト
EP1664091A1 (en) 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007003054A1 (en) 2005-07-06 2007-01-11 Shoichet Molly S Method of biomolecule immobilization on polymers using click-type chemistry
US20070060658A1 (en) 2005-08-31 2007-03-15 Diaz David D Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
DK2032155T3 (en) 2006-06-09 2015-03-02 Novartis Ag Stabilized insulin-like growth factor polypeptides
ITMI20061726A1 (it) * 2006-09-11 2008-03-12 Fidia Farmaceutici Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry
CN101600428A (zh) 2007-02-09 2009-12-09 Irm责任有限公司 作为通道活化蛋白酶抑制剂的化合物和组合物
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
AR065860A1 (es) 2007-03-29 2009-07-08 Novartis Ag 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
AU2008258548B2 (en) 2007-06-08 2014-07-10 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
WO2009095954A2 (ja) 2008-01-31 2009-08-06 Appside Co., Ltd. データ入力装置、データ入力方法ならびにデータ入力プログラムおよびこれを記録した記録媒体
EP2596805B1 (en) 2008-02-01 2021-10-27 Ascendis Pharma A/S Prodrug comprising a drug-linker conjugate
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
US20110230497A1 (en) 2008-11-07 2011-09-22 H. Lundbeck A/S Biologically active amides
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8648144B2 (en) 2009-02-21 2014-02-11 Sofradim Production Crosslinked fibers and method of making same by extrusion
WO2010099818A1 (en) 2009-03-03 2010-09-10 Ao Technology Ag Thermoreversible polysaccharide hydrogel
WO2010102663A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Piperazine derivatives for use in therapy
IN2012DN00352A (es) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
TW201113280A (en) 2009-07-03 2011-04-16 Nensius Res As Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the CNS
BR112012002280B1 (pt) * 2009-07-31 2020-04-07 Ascendis Pharma As hidrogel insolúvel em água baseado em polietileno glicol biodegradável, seu processo de preparação, conjugado, composto ligado a veículo e composição farmacêutica.
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
EP2459225A1 (en) 2009-07-31 2012-06-06 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
PE20120918A1 (es) 2009-07-31 2012-08-14 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
MX2012004499A (es) 2009-10-29 2012-05-29 Ascendis Pharma As Esterilizacion de hidrogeles biodegradables.
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
EP2563753B9 (en) 2010-04-27 2016-07-06 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
CN103025164B (zh) 2010-05-05 2017-03-08 普罗林科斯有限责任公司 从固体支撑物中药物的控制释放
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
US9388276B2 (en) 2011-02-25 2016-07-12 University Of Massachusetts Monomers and polymers for functional polycarbonates and poly(ester-carbonates) and PEG-co-polycarbonate hydrogels
CZ304072B6 (cs) 2011-04-26 2013-09-25 Contipro Biotech S.R.O. Amfoterní materiál na bázi sítované kyseliny hyaluronové, zpusob jeho prípravy, materiály obsahující aktivní cinidla uzavrené v síti hyaluronanu, zpusob jejich prípravy a jejich pouzití
JPWO2012165462A1 (ja) 2011-05-31 2015-02-23 国立大学法人 東京大学 ハイドロゲル及びその製造方法
WO2012173952A1 (en) 2011-06-13 2012-12-20 Emory University Piperazine derivatives, compositions, and uses related thereto
KR20140082649A (ko) 2011-08-12 2014-07-02 아센디스 파마 에이에스 프로스타사이클린의 서방형 조성물
JP6158185B2 (ja) 2011-09-07 2017-07-05 プロリンクス エルエルシー 生分解性架橋を有するヒドロゲル
US20130066063A1 (en) 2011-09-09 2013-03-14 John Cooke Hodges Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides
RU2014118642A (ru) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С Предотвращение и лечение глазных нарушений
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
JP2013116858A (ja) 2011-12-01 2013-06-13 Dainippon Sumitomo Pharma Co Ltd Ｂｄｎｆ様低分子化合物を含有する治療薬
CN104136606A (zh) 2011-12-01 2014-11-05 安吉奥开米公司 靶向的艾杜糖-2-硫酸酯酶化合物
WO2013171485A1 (en) 2012-05-18 2013-11-21 Medical Research Council Methods of incorporating an amino acid comprising a bcn group into a polypeptide using an orthogonal codon encoding it and an orthorgonal pylrs synthase.
US10980860B2 (en) 2012-10-11 2021-04-20 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
SG11201501914XA (en) 2012-10-11 2015-05-28 Ascendis Pharma Ophthalmology Division As Vegf neutralizing prodrugs for the treatment of ocular conditions
WO2014059446A1 (en) 2012-10-12 2014-04-17 Case Western Reserve University Biodegradable hydrogel for polynucleotide delivery
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20150352246A1 (en) 2013-01-22 2015-12-10 Prolynx Llc Sealants having controlled degration
PT2953976T (pt) * 2013-02-08 2021-06-23 Novartis Ag Sítios específicos de modificação de anticorpos para preparar imunoconjugados
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
EP2988783A1 (en) 2013-04-22 2016-03-02 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
US20160089446A1 (en) 2013-04-22 2016-03-31 Ascendis Pharma A/S Modified Hydrogels
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
CN104292454B (zh) 2013-07-17 2017-12-01 北京键凯科技股份有限公司 聚乙二醇‑环辛炔衍生物
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
EP3024847A1 (en) 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
JP2016172783A (ja) 2013-08-08 2016-09-29 生化学工業株式会社 組織膨隆材
US20180042996A1 (en) 2013-10-08 2018-02-15 Ascendis Pharma Osteoarthritis Division A/S Hydrogel-Linked IL-1ra Prodrug
KR20160075665A (ko) 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
WO2015067791A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
CA2940550C (en) 2014-02-26 2023-01-17 University Of Massachusetts Degradable hydrogel with predictable tuning of properties, and compositions and methods thereof
EP3193941A1 (en) 2014-08-06 2017-07-26 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016025752A1 (en) 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20170368189A1 (en) 2015-01-09 2017-12-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
WO2016161372A1 (en) * 2015-04-01 2016-10-06 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
US11298427B2 (en) 2015-05-29 2022-04-12 Ascendis Pharma A/S Prodrugs comprising a pyroglutamate linker
EP3377047A1 (en) 2015-11-20 2018-09-26 Cristal Delivery B.V. Nanoparticles with active targeting
CA3016814A1 (en) 2016-03-16 2017-09-21 Prolynx Llc Extended release conjugates of exenatide analogs
WO2018011266A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط

Also Published As

Publication number Publication date
RU2019136872A3 (es) 2021-08-31
SG11201908740VA (en) 2019-11-28
AR111481A1 (es) 2019-07-17
AU2018255933B2 (en) 2021-09-30
PE20211281A1 (es) 2021-07-19
US20180303945A1 (en) 2018-10-25
RU2019136872A (ru) 2021-05-21
IL269991B2 (en) 2023-07-01
MA50260A (fr) 2020-02-26
EA202192099A3 (ru) 2022-02-28
MX2019012447A (es) 2020-01-13
CO2019011577A2 (es) 2019-10-31
AU2018255933A1 (en) 2019-10-17
PH12019502325A1 (en) 2020-07-06
CN110603060A (zh) 2019-12-20
EA202192099A2 (ru) 2021-11-30
WO2018193408A1 (en) 2018-10-25
CU20190082A7 (es) 2020-10-20
JOP20190245A1 (ar) 2019-10-15
CA3057590A1 (en) 2018-10-25
JP7323453B2 (ja) 2023-08-08
US20230201353A1 (en) 2023-06-29
US10751417B2 (en) 2020-08-25
DOP2019000268A (es) 2020-02-16
UY37686A (es) 2018-11-30
CR20190479A (es) 2019-11-20
EA201992484A1 (ru) 2020-02-25
IL269991A (es) 2019-12-31
US20200376129A1 (en) 2020-12-03
IL269991B1 (en) 2023-03-01
KR20190137888A (ko) 2019-12-11
ECSP19075134A (es) 2019-10-31
EP3612233A1 (en) 2020-02-26
JP2020517623A (ja) 2020-06-18
BR112019021810A2 (pt) 2020-05-26
CL2019002969A1 (es) 2020-02-07
TW201842935A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
PE20191837A1 (es) Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
PE20211280A1 (es) Sales cristalinas de un inhibidor de calicreina plasmatica
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
HN2012001037A (es) Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
AR061419A1 (es) Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3
PE20211646A1 (es) Administracion sostenida de polipeptidos similares a la angiopoyetina 3
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CU20160166A7 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2019000727A1 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos.
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
AR085249A1 (es) Derivados de oxima como agonistas de gpr119
AR085822A1 (es) Moduladores alostericos positivos del receptor nicotinico de acetilcolina
ECSP23073082A (es) Nuevos moduladores alostéricos negativos ciclopenta[c]pirrol de NR2B
CU20160170A7 (es) Derivados de carboxamida
ECSP055713A (es) Nuevos compuestos antimicobacterianos